Which has better earnings & valuation, LFMD or DCGO?

LifeMD has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 1.08 $14.35M $0.05 86.90 DocGo $322.20M 0.20 -$182.40M -$1.91 N/A

Is LFMD or DCGO more profitable?

LifeMD has a net margin of 2.37% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% DocGo -62.23% -44.09% -29.14%

Do analysts prefer BNR or DCGO?

DocGo has a consensus price target of $2.38, indicating a potential upside of 263.15%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to BNR or DCGO?

In the previous week, DocGo had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for DocGo and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.93 beat DocGo's score of 0.63 indicating that Burning Rock Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, DCGO or BDSX?

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.20 -$182.40M -$1.91 N/A Biodesix $88.50M 1.91 -$35.26M -$4.06 N/A

Is DCGO or BDSX more profitable?

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Biodesix -33.26% -2,101.40% -35.65%

Does the media refer more to DCGO or BDSX?

In the previous week, DocGo had 1 more articles in the media than Biodesix. MarketBeat recorded 3 mentions for DocGo and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.55 beat DocGo's score of 0.63 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, XGN or DCGO?

Exagen has higher earnings, but lower revenue than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.77 -$19.95M -$0.89 N/A DocGo $322.20M 0.20 -$182.40M -$1.91 N/A

Is XGN or DCGO more profitable?

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% DocGo -62.23% -44.09% -29.14%

Which has preferable earnings and valuation, PIII or DCGO?

P3 Health Partners has higher revenue and earnings than DocGo. P3 Health Partners is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio P3 Health Partners $1.46B 0.07 -$147.95M -$38.60 N/A DocGo $322.20M 0.20 -$182.40M -$1.91 N/A

Is PIII or DCGO more profitable?

P3 Health Partners has a net margin of -8.57% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat P3 Health Partners' return on equity. Company Net Margins Return on Equity Return on Assets P3 Health Partners -8.57% -302.33% -19.99% DocGo -62.23% -44.09% -29.14%

Does the media prefer PIII or DCGO?

In the previous week, P3 Health Partners had 1 more articles in the media than DocGo. MarketBeat recorded 4 mentions for P3 Health Partners and 3 mentions for DocGo. DocGo's average media sentiment score of 0.63 beat P3 Health Partners' score of 0.22 indicating that DocGo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment P3 Health Partners 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DocGo (DCGO) Competitors

$0.65 0.00 (-0.50%)

As of 03:24 PM Eastern

Compare

DCGO vs. LFMD, BNR, BDSX, XGN, and PIII

Should you buy DocGo stock or one of its competitors? MarketBeat compares DocGo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DocGo include LifeMD (LFMD), Burning Rock Biotech (BNR), Biodesix (BDSX), Exagen (XGN), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry.

How does DocGo compare to LifeMD?

LifeMD (NASDAQ:LFMD) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

LifeMD has a net margin of 2.37% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
DocGo	-62.23%	-44.09%	-29.14%

LifeMD has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.08	$14.35M	$0.05	86.90
DocGo	$322.20M	0.20	-$182.40M	-$1.91	N/A

LifeMD presently has a consensus target price of $9.14, indicating a potential upside of 110.42%. DocGo has a consensus target price of $2.38, indicating a potential upside of 263.15%. Given DocGo's higher possible upside, analysts clearly believe DocGo is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 18.4% of LifeMD shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, LifeMD had 8 more articles in the media than DocGo. MarketBeat recorded 11 mentions for LifeMD and 3 mentions for DocGo. DocGo's average media sentiment score of 0.63 beat LifeMD's score of 0.43 indicating that DocGo is being referred to more favorably in the news media.

Company	Overall Sentiment
LifeMD	Neutral
DocGo	Positive

LifeMD has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market. Comparatively, DocGo has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

Summary

LifeMD beats DocGo on 11 of the 16 factors compared between the two stocks.

How does DocGo compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Burning Rock Biotech has a net margin of -10.27% compared to DocGo's net margin of -62.23%. Burning Rock Biotech's return on equity of -9.98% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-10.27%	-9.98%	-6.69%
DocGo	-62.23%	-44.09%	-29.14%

Burning Rock Biotech has higher earnings, but lower revenue than DocGo. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.29	-$7.92M	-$0.79	N/A
DocGo	$322.20M	0.20	-$182.40M	-$1.91	N/A

DocGo has a consensus price target of $2.38, indicating a potential upside of 263.15%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, DocGo had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for DocGo and 2 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.93 beat DocGo's score of 0.63 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Burning Rock Biotech has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, DocGo has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 3.8% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Burning Rock Biotech beats DocGo on 9 of the 16 factors compared between the two stocks.

How does DocGo compare to Biodesix?

DocGo (NASDAQ:DCGO) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

DocGo presently has a consensus price target of $2.38, suggesting a potential upside of 263.15%. Biodesix has a consensus price target of $22.00, suggesting a potential upside of 35.14%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Biodesix	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

56.4% of DocGo shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 3.8% of DocGo shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Biodesix	-33.26%	-2,101.40%	-35.65%

DocGo has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.20	-$182.40M	-$1.91	N/A
Biodesix	$88.50M	1.91	-$35.26M	-$4.06	N/A

In the previous week, DocGo had 1 more articles in the media than Biodesix. MarketBeat recorded 3 mentions for DocGo and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.55 beat DocGo's score of 0.63 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

DocGo beats Biodesix on 10 of the 15 factors compared between the two stocks.

How does DocGo compare to Exagen?

Exagen (NASDAQ:XGN) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
DocGo	-62.23%	-44.09%	-29.14%

Exagen presently has a consensus price target of $9.25, suggesting a potential upside of 90.09%. DocGo has a consensus price target of $2.38, suggesting a potential upside of 263.15%. Given DocGo's higher possible upside, analysts clearly believe DocGo is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Exagen has higher earnings, but lower revenue than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.77	-$19.95M	-$0.89	N/A
DocGo	$322.20M	0.20	-$182.40M	-$1.91	N/A

75.3% of Exagen shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 12.6% of Exagen shares are held by insiders. Comparatively, 3.8% of DocGo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Exagen has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, DocGo has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

In the previous week, DocGo had 2 more articles in the media than Exagen. MarketBeat recorded 3 mentions for DocGo and 1 mentions for Exagen. Exagen's average media sentiment score of 1.43 beat DocGo's score of 0.63 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Positive
DocGo	Positive

Summary

Exagen beats DocGo on 11 of the 16 factors compared between the two stocks.

How does DocGo compare to P3 Health Partners?

P3 Health Partners (NASDAQ:PIII) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

P3 Health Partners has a net margin of -8.57% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-8.57%	-302.33%	-19.99%
DocGo	-62.23%	-44.09%	-29.14%

P3 Health Partners has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, DocGo has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

In the previous week, P3 Health Partners had 1 more articles in the media than DocGo. MarketBeat recorded 4 mentions for P3 Health Partners and 3 mentions for DocGo. DocGo's average media sentiment score of 0.63 beat P3 Health Partners' score of 0.22 indicating that DocGo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

P3 Health Partners has higher revenue and earnings than DocGo. P3 Health Partners is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.07	-$147.95M	-$38.60	N/A
DocGo	$322.20M	0.20	-$182.40M	-$1.91	N/A

P3 Health Partners presently has a consensus price target of $14.00, indicating a potential upside of 0.18%. DocGo has a consensus price target of $2.38, indicating a potential upside of 263.15%. Given DocGo's stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 17.8% of P3 Health Partners shares are held by insiders. Comparatively, 3.8% of DocGo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

DocGo beats P3 Health Partners on 10 of the 16 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$64.58M	$8.54B	$6.41B	$12.57B
Dividend Yield	N/A	2.99%	2.75%	5.26%
P/E Ratio	-0.34	21.60	21.27	26.27
Price / Sales	0.20	20.05	560.98	113.99
Price / Cash	11.44	88.04	43.49	56.90
Price / Book	0.58	5.93	10.58	7.32
Net Income	-$182.40M	$183.47M	$3.56B	$336.95M
7 Day Performance	3.73%	3.24%	2.91%	3.44%
1 Month Performance	-7.51%	13.08%	6.26%	7.18%
1 Year Performance	-51.91%	6.33%	36.44%	37.43%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	3.3641 of 5 stars	$0.65 -0.5%	$2.38 +263.1%	-51.7%	$64.58M	$322.20M	N/A	3,568
LFMD LifeMD	4.354 of 5 stars	$4.18 +2.6%	$9.14 +118.9%	-60.0%	$201.95M	$194.05M	83.54	230	Trending News Analyst Forecast Analyst Revision
BNR Burning Rock Biotech	1.4254 of 5 stars	$14.88 -8.8%	N/A	+230.1%	$156.54M	$77.16M	N/A	1,390	Upcoming Earnings Gap Up
BDSX Biodesix	3.7621 of 5 stars	$14.93 -1.6%	$22.00 +47.4%	+133.0%	$150.94M	$88.50M	N/A	220	Positive News
XGN Exagen	4.2925 of 5 stars	$4.27 flat	$9.25 +116.6%	-24.2%	$103.16M	$66.57M	N/A	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors